Vitamin D Boosts Alendronate Tail Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis

Catalano, Antonino; Bellone, Federica; Santoro, Domenico; Schwarz, Peter; Gaudio, Agostino; Basile, Giorgio; Sottile, M. C.; Stoian, Sabrina Atena; Corica, Francesco; Morabito, Nunziata

doi:10.3390/nu13061878

Cited by 10 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Пре-и постменопауза является использование витамина D, дефицит которого связан с клиническими проявлениями климактерического синдрома [15]. При этом существует большое число исследований, посвященных использованию препаратов витамина D в терапии поздних проявлений КС, в первую очередь остеопороза [16], а также вагинальной атрофии [17], сердечно-сосудистых заболеваний [18], метаболического синдрома [19]. Вместе с тем сведения о влиянии витамина D на ранние симптомы КС единичны и противоречивы [20,21].…”

Section: Introductionunclassified

The effect of vitamin D on the early clinical manifestations of menopausal syndrome and the production of cytokines, involved in bone remodeling

Maylyan,

Lesnichenko,

Dzhelomanova

et al. 2023

Medicinskij sovet

View full text Add to dashboard Cite

Introduction. The problem of early manifestations of menopausal syndrome is due to the high prevalence among postmenopausal women, a wide range of clinical manifestations, a sharp decrease in the quality of life, not always sufficient effectiveness of menopausal hormone therapy (MHT) in the presence of restrictions on its use.The aim. To evaluate the dynamics of clinical manifestations of menopausal syndrome and to determine the pathogenetic effects of vitamin D preparation when used in combination with menopausal hormone therapy in women of early postmenopausal age with menopausal syndrome.Materials and methods. 154 women were examined, of which 81 were characterized by the presence of clinical manifestations of menopausal syndrome. All women with menopausal syndrome received menopausal hormone therapy with estradiol and didrogesterone drug for 6 months, while 39 women additionally also took the vitamin D drug. Before and after therapy in patients with menopausal syndrome, the prevalence of symptoms of the Green scale was assessed. Concentrations of 25(OH) D, osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL) were determined in the blood serum of all women.Results and discussion. The use of MHT by women with menopausal syndrome leads to a decrease in the frequency of registration of a number of symptoms of the Green scale (p < 0.05). At the same time, a decrease in the frequency of registration of individual complaints is found only in the group of women who, along with MYT, received a vitamin D preparation (p < 0.05). Taking the vitamin D preparation is accompanied by an increase in its initially reduced serum concentrations to normal values (p < 0.001). The addition of cholecalciferol to the complex therapy of menopausal syndrome ensures the normalization of RANKL levels by reducing its production in the dynamics of treatment (p < 0.05) A decrease in the concentration of RANKL in response to the complex intake of a hormonal drug and cholecalciferol caused higher OPG/RANKL index values in the basic group by the end of therapy than in women of the comparison group (p < 0.01).Conclusions. The obtained effects of vitamin D preparation when prescribed in combination with menopausal hormone therapy (reduction of the frequency of symptoms of menopausal syndrome, reduction of initially elevated levels of RANKL) indicate the expediency of its use in the treatment of early manifestations of menopausal syndrome.

show abstract